New insider activity at MBX Biosciences, Inc. ( (MBX) ) has taken place on February 6, 2025.
Director P. Kent Hawryluk has made a significant investment in MBX Biosciences, Inc. by purchasing 50,000 shares, valuing the transaction at $534,500.
Recent Updates on MBX stock
MBX Biosciences reported positive results from its Phase 1 clinical trial of MBX 1416, a long-acting glucagon-like peptide 1 receptor antagonist aimed at treating PBH. The trial demonstrated that MBX 1416 was generally well-tolerated and had a favorable safety profile, with no dose-related serious adverse events and mild to moderate treatment-emergent adverse events. The study showed a pharmacodynamic effect in healthy volunteers, which may offer therapeutic benefits in PBH patients. These results have likely contributed to recent changes in the stock’s price target, as the successful trial outcomes suggest potential future success in patient treatment, enhancing investor confidence. Additionally, MBX Biosciences’ financial updates, including their Q3 earnings per share which exceeded consensus expectations and projected cash runway into mid-2027, further bolster the stock’s outlook.
More about MBX Biosciences, Inc.
YTD Price Performance: -40.11%
Average Trading Volume: 250,528
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $365.3M